Please assess the completion status of the following clinical trial:

Trial Title: High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients of any ethnic group aged between 18 and 65 years~* HIV-positive patients with malignant diseases of the blood (NHL, Hodgkin disease, plasmocytoma, acute and chronic leukaemia) who failed to achieve complete remission (CR) after standard-dose first-line chemotherapy or had a chemosensitive relapse after an initial CR~* Patients must receive HAART~Exclusion Criteria:~* Any of the following conditions:~  * congestive heart failure (NYHA \> II)~ * documented EBV, HBV or HCV infection (only for allogeneic PBSCT)~ * creatinine clearance \< 60 ml/min~ * left ventricular ejection fraction \< 40%~ * bilirubin \> 2 mg/dl~* Severe opportunistic infection~* More than 10% of bone marrow involved with lymphoma~* Between 2 and 5 10\^6 autologous CD34+ cells/kg BW obtained after leukapheresis and CD34 enrichment~* Women of child.bearing potential not under adequate contraceptive protection~* Women who are pregnant or breast feeding~* Known history of drug-, medication- or alcohol abuse within the last 12 months preceding the study~* Participation in another study with an investigational product within less than one month prior to this study~* Simultaneous participation in a study with an investigational drug~* Presence of any disease likely to require procedures altering the schedule of the protocol~* Patients with a history of seizures, central nervous system disorders or psychiatric disability thought to be clinically significant in the opinion of the investigator~* Patients with limited mental capacity to the extent that he/she cannot provide informed consent or information regarding adverse events of the study medication~* Patients with any clinically meaningful renal, hepatic, respiratory or cardiovascular disease~* Patients who have previously been admitted to this study~* Patients who will not accept transfusions of blood products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).